Skip to content

Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study

Maraviroc may work as PrEP in combination with another drug – but probably not by itself

Roy Gulick presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Experimental TLR7 agonist suppresses HIV-like virus in monkeys after ART interruption

Dolutegravir safe and highly effective in older children

Dolutegravir safe and highly effective in older children

TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

Joel Gallant presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Dose-finding trials of antibody-based drugs for HIV prevention will start soon

John Mascola presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy

David Margolis presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Combination nanotherapy drastically reduces the amount of HIV produced by cells in mice

Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model